AbbVie (NYSE: ABBV) and Aliada Therapeutics announce a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. Aliada’s lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of Alzheimer’s disease. Aliada is advancing therapeutic candidates using its Modular Delivery (MODEL™) platform, engineered for high-precision CNS drug delivery.
Read the full article: AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer’s Disease and Neuroscience Pipeline //
Source: https://www.prnewswire.com/news-releases/abbvie-to-acquire-aliada-therapeutics-strengthening-focus-in-alzheimers-disease-and-neuroscience-pipeline-302288180.html